Dyslipidemia – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Dyslipidemia – Pipeline Review, H1 2020’, provides an overview of the Dyslipidemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Dyslipidemia

– The report reviews pipeline therapeutics for Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Dyslipidemia therapeutics and enlists all their major and minor projects

– The report assesses Dyslipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Dyslipidemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Dyslipidemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

89bio Inc

AbbVie Inc

ABIONYX Pharma SA

Acasti Pharma Inc

AD Pharmaceuticals Co Ltd

Affina Biotechnologies Inc

Afimmune Biopharma Ltd

Akcea Therapeutics Inc

Akeso Biopharma Inc

Amarin Corp Plc

Arrowhead Pharmaceuticals Inc

AstraZeneca Plc

AVVA Pharmaceuticals AG

BCWorld Pharm Co Ltd

BioRestorative Therapies Inc

Boryung Pharmaceutical Co Ltd

Cadila Healthcare Ltd

Cadila Pharmaceuticals Ltd

Cardax Inc

Celon Pharma SA

Centaurus Therapeutics Inc

Centeer BioTherapeutics Ltd Co

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Corbus Pharmaceuticals Inc

Corvidia Therapeutics Inc

CVI Pharmaceuticals US Inc

Daewon Pharmaceutical Co Ltd

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Delivra Corp

DongKoo Bio & Pharma Co Ltd

Eli Lilly and Co

Elyson Pharmaceutical Co Ltd

Esperion Therapeutics Inc

Gilead Sciences Inc

Golden Biotechnology Corp

Handok Inc

Hanlim Pharm Co Ltd

Hanmi Pharmaceuticals Co Ltd

Ildong Pharmaceutical Co Ltd

Inovio Pharmaceuticals Inc

InStar Technologies AS

Jeil Pharmaceutical Co Ltd

Jenrin Discovery Inc

Jiangsu Hengrui Medicine Co Ltd

Kolmar Pharma Co Ltd

Korea United Pharm Inc

Kotobuki Pharmaceutical Co Ltd

Kowa Co Ltd

Krisani Bio Sciences Pvt Ltd

Kuhnil Pharmaceutical Co Ltd

Kyorin Pharmaceutical Co Ltd

Kyung Dong Co Ltd

LG Chem Ltd

LipimetiX Development Inc

Matinas BioPharma Holdings Inc

MD Healthcare Inc

Micelle BioPharma Inc

Mochida Pharmaceutical Co Ltd

MYR GmbH

NeuroBo Pharmaceuticals Inc

Nippon Chemiphar Co Ltd

NorthSea Therapeutics BV

NovalGen Ltd

Novartis AG

NuSirt Biopharma Inc

Omeros Corp

OncoImmune Inc

Pfizer Inc

Pharmena SA

Regeneron Pharmaceuticals Inc

Reneo Pharmaceuticals Inc

Sequor Pharmaceuticals LLC

Shanghai Institute of Pharmaceutical Industry

Shanghai Junshi Bioscience Co Ltd

Shenzhen Salubris Pharmaceuticals Co Ltd

Shifa Biomedical Corp

SJT Molecular Research SL

Staten Biotechnology BV

Suzhou Ribo Life Sciences Co Ltd

Sveikatal Inc

Synokem Pharmaceuticals Ltd

Tetranov International Inc

Viking Therapeutics Inc

Yuhan Corp

Table of Contents

Table of Contents

Introduction

Dyslipidemia - Overview

Dyslipidemia - Therapeutics Development

Dyslipidemia - Therapeutics Assessment

Dyslipidemia - Companies Involved in Therapeutics Development

Dyslipidemia - Drug Profiles

Dyslipidemia - Dormant Projects

Dyslipidemia - Discontinued Products

Dyslipidemia - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Dyslipidemia, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Dyslipidemia – Pipeline by 89bio Inc, H1 2020

Dyslipidemia – Pipeline by AbbVie Inc, H1 2020

Dyslipidemia – Pipeline by ABIONYX Pharma SA, H1 2020

Dyslipidemia – Pipeline by Acasti Pharma Inc, H1 2020

Dyslipidemia – Pipeline by AD Pharmaceuticals Co Ltd, H1 2020

Dyslipidemia – Pipeline by Yuhan Corp, H1 2020

Dyslipidemia – Dormant Projects, H1 2020

Dyslipidemia – Dormant Projects, H1 2020 (Contd..1), H1 2020

Dyslipidemia – Dormant Projects, H1 2020 (Contd..2), H1 2020

Dyslipidemia – Dormant Projects, H1 2020 (Contd..3), H1 2020

Dyslipidemia – Dormant Projects, H1 2020 (Contd..4), H1 2020

Dyslipidemia – Dormant Projects, H1 2020 (Contd..5), H1 2020

Dyslipidemia – Dormant Projects, H1 2020 (Contd..6), H1 2020

Dyslipidemia – Dormant Projects, H1 2020 (Contd..7), H1 2020

Dyslipidemia – Dormant Projects, H1 2020 (Contd..8), H1 2020

Dyslipidemia – Dormant Projects, H1 2020 (Contd..9), H1 2020

Dyslipidemia – Dormant Projects, H1 2020 (Contd..10), H1 2020

Dyslipidemia – Dormant Projects, H1 2020 (Contd..11), H1 2020

Dyslipidemia – Discontinued Products, H1 2020

Dyslipidemia – Discontinued Products, H1 2020 (Contd..1), H1 2020

Dyslipidemia – Discontinued Products, H1 2020 (Contd..2), H1 2020

Dyslipidemia – Discontinued Products, H1 2020 (Contd..3), H1 2020

List of Figures

List of Figures

Number of Products under Development for Dyslipidemia, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports